Literature DB >> 34133077

Long-lived macrophage reprogramming drives spike protein-mediated inflammasome activation in COVID-19.

Sebastian J Theobald1,2, Alexander Simonis1,2, Theodoros Georgomanolis3, Christoph Kreer4, Matthias Zehner4, Hannah S Eisfeld1,2, Marie-Christine Albert5,6, Jason Chhen1,2, Susanne Motameny3, Florian Erger3,7, Julia Fischer1,2,8, Jakob J Malin1,2, Jessica Gräb1,2, Sandra Winter1,2, Andromachi Pouikli9, Friederike David3, Boris Böll1, Philipp Koehler1,2,5, Kanika Vanshylla4, Henning Gruell4, Isabelle Suárez1,8, Michael Hallek1, Gerd Fätkenheuer1,8, Norma Jung1,8, Oliver A Cornely1,2,5,8, Clara Lehmann1,2,8, Peter Tessarz5,9, Janine Altmüller3, Peter Nürnberg2,3, Hamid Kashkar5,6, Florian Klein4,8, Manuel Koch10,11, Jan Rybniker1,2,8.   

Abstract

Innate immunity triggers responsible for viral control or hyperinflammation in COVID-19 are largely unknown. Here we show that the SARS-CoV-2 spike protein (S-protein) primes inflammasome formation and release of mature interleukin-1β (IL-1β) in macrophages derived from COVID-19 patients but not in macrophages from healthy SARS-CoV-2 naïve individuals. Furthermore, longitudinal analyses reveal robust S-protein-driven inflammasome activation in macrophages isolated from convalescent COVID-19 patients, which correlates with distinct epigenetic and gene expression signatures suggesting innate immune memory after recovery from COVID-19. Importantly, we show that S-protein-driven IL-1β secretion from patient-derived macrophages requires non-specific monocyte pre-activation in vivo to trigger NLRP3-inflammasome signaling. Our findings reveal that SARS-CoV-2 infection causes profound and long-lived reprogramming of macrophages resulting in augmented immunogenicity of the SARS-CoV-2 S-protein, a major vaccine antigen and potent driver of adaptive and innate immune signaling.
© 2021 The Authors. Published under the terms of the CC BY 4.0 license.

Entities:  

Keywords:  NLRP3; SARS-CoV-2; inflammasome; innate immunity; macrophage

Year:  2021        PMID: 34133077     DOI: 10.15252/emmm.202114150

Source DB:  PubMed          Journal:  EMBO Mol Med        ISSN: 1757-4676            Impact factor:   12.137


  24 in total

Review 1.  NLRP3 inflammasome activation and SARS-CoV-2-mediated hyperinflammation, cytokine storm and neurological syndromes.

Authors:  Debashis Dutta; Jianuo Liu; Huangui Xiong
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2022-06-15

Review 2.  Pulmonary and Systemic Pathology in COVID-19.

Authors:  Danny Jonigk; Christopher Werlein; Peter D Lee; Hans-Ulrich Kauczor; Florian Länger; Maximilian Ackermann
Journal:  Dtsch Arztebl Int       Date:  2022-06-24       Impact factor: 8.251

Review 3.  Therapeutic Targeting of Innate Immune Receptors Against SARS-CoV-2 Infection.

Authors:  Mariya Farooq; Abdul Waheed Khan; Bilal Ahmad; Moon Suk Kim; Sangdun Choi
Journal:  Front Pharmacol       Date:  2022-06-30       Impact factor: 5.988

4.  The IL-1β, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19.

Authors:  Christoph Schultheiß; Edith Willscher; Lisa Paschold; Cornelia Gottschick; Bianca Klee; Svenja-Sibylla Henkes; Lidia Bosurgi; Jochen Dutzmann; Daniel Sedding; Thomas Frese; Matthias Girndt; Jessica I Höll; Michael Gekle; Rafael Mikolajczyk; Mascha Binder
Journal:  Cell Rep Med       Date:  2022-06-21

5.  The role of IL-1 family of cytokines and receptors in pathogenesis of COVID-19.

Authors:  Shima Makaremi; Ali Asgarzadeh; Hamed Kianfar; Alireza Mohammadnia; Vahid Asghariazar; Elham Safarzadeh
Journal:  Inflamm Res       Date:  2022-06-25       Impact factor: 6.986

Review 6.  Targeting the NLRP3 inflammasome in cardiovascular diseases.

Authors:  Stefano Toldo; Eleonora Mezzaroma; Leo F Buckley; Nicola Potere; Marcello Di Nisio; Giuseppe Biondi-Zoccai; Benjamin W Van Tassell; Antonio Abbate
Journal:  Pharmacol Ther       Date:  2021-12-11       Impact factor: 13.400

Review 7.  Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines.

Authors:  Adam N Pelletier; Rafick P Sekaly; Jeffrey A Tomalka
Journal:  Curr Opin Virol       Date:  2021-12-11       Impact factor: 7.090

Review 8.  Host cell-intrinsic innate immune recognition of SARS-CoV-2.

Authors:  Emily A Madden; Michael S Diamond
Journal:  Curr Opin Virol       Date:  2021-11-11       Impact factor: 7.090

Review 9.  Emerging Role of Platelet-Endothelium Interactions in the Pathogenesis of Severe SARS-CoV-2 Infection-Associated Myocardial Injury.

Authors:  Theresa M Rossouw; Ronald Anderson; Pravin Manga; Charles Feldman
Journal:  Front Immunol       Date:  2022-02-04       Impact factor: 7.561

10.  [Post-corona fatigue-a familiar picture in a new guise?]

Authors:  Barbara Buchberger; Ruben Zwierlein; Volker Rohde
Journal:  Onkologe (Berl)       Date:  2022-02-17       Impact factor: 0.170

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.